Effectiveness and Safety of Topical Halobetasol Propionate in the Treatment of Patients With Psoriasis
Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
The Psoriasis and a chronic dermatosis characterized by abnormal proliferation of cells
epithelial, vessel dilation and inflammation locally, which presents erythematous-scaly
lesions in various areas of the body, preferably in the scalp, region and religious joints as
elbows and knees. It occurs equally in both sexes and can appear at any age, and the mean age
for the onset of the disease and around 27.3 years.
The halobetasol propionate and an ultra-potent corticoid. Its chemical structure and similar
to the Clobetasol corticoid this, until then classified as the most potent corticoid used
worldwide in clinical practice. However, the molecular structure of Halobetasol gives it
increased its activity antiinflammatory and anti-proliferative.
The objective of this study is evaluating the efficacy and tolerability of the drug
Halobetasol propionate cream formulation as a treatment in patients with plaque psoriasis
mild to moderate, compared to the substance of similar power, Clobetasol propionate - Psorex
- Cream.